Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04693234 |
|---|---|
| Brief Title: | AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer |
| First Submitted : | December 22, 2020 |
| First Submitted that Met QC Criteria : | December 30, 2020 |
| First Posted : | January 5, 2021 |
| Last Update Submitted that Met QC Criteria : | July 27, 2022 |
| Last Update Posted : | July 28, 2022 |